LEGN — Recent News Coverage
All news mentioning LEGN in ESEN's AI-graded feed
News stories with LEGN as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on LEGN. See /coverage/LEGN for the 30-day aggregate.
MANILATIMES.NET
·
2026-08-12
LOW
NEUTRAL
CORR0.15
ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments
$LEGN
◈ ESEN AI
ADARx Pharmaceuticals announced organizational changes through board and executive leadership appointments, including Dr. Ying Huang joining the Board of Directors. These moves represent routine corporate governance act…
SEEKINGALPHA.COM
·
2026-08-12
NEUTRAL
BULLISH
CORR0.45
Legend’s Pipeline Is Starting To Matter (NASDAQ:LEGN)
$LEGN
◈ ESEN AI
Legend Biotech (LEGN) is undergoing a significant operational inflection as it pivots from a cash-burn biotech model toward commercial profitability anchored by CARVYKTI, its cell therapy asset. This transition represen…
SEEKINGALPHA.COM
·
2026-08-11
LOW
NEUTRAL
CORR0.42
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
$LEGN
◈ ESEN AI
Legend Biotech (LEGN) released its Q2 2026 earnings call transcript, a scheduled procedural disclosure that provides historical financial and operational commentary rather than forward-looking catalysts. Earnings call t…
FINANCE.YAHOO.COM
·
2026-07-28
NEUTRAL
NEUTRAL
CORR0.15
Leadership changes afoot at two CGT biotechs
$LEGN
$SRPT
◈ ESEN AI
Legend Biotech's unexpected CEO departure introduces leadership uncertainty that typically pressures stock valuations in the near term, particularly for smaller-cap biotechs where executive continuity signals operationa…
MANILATIMES.NET
·
2026-07-28
NEUTRAL
NEUTRAL
CORR0.35
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
$LEGN
◈ ESEN AI
Legend Biotech (LEGN) announced a scheduled earnings call for August 11, 2026, to discuss second-quarter 2026 financial performance. This is a routine disclosure announcement with no material guidance revision, strategi…
SEEKINGALPHA.COM
·
2026-07-24
NEUTRAL
BULLISH
CORR0.52
Legend Biotech: Why I'm Ready To Go Long Again (NASDAQ:LEGN)
$LEGN
◈ ESEN AI
Legend Biotech (LEGN) has demonstrated meaningful commercial momentum in Q2, with Carvykti demand tracking ahead of initial expectations for the approved CAR-T therapy. This uptick in revenue generation signals market a…
SEEKINGALPHA.COM
·
2026-07-08
NEUTRAL
BULLISH
CORR0.52
A New Look At Legend Biotech: Plenty Of Upside For Carvykti (NASDAQ:LEGN)
$LEGN
◈ ESEN AI
Legend Biotech (LEGN) is receiving analyst attention for its commercial pipeline centered on Carvykti, a CAR-T cell therapy designed for multiple myeloma treatment. The article suggests meaningful upside potential drive…
MANILATIMES.NET
·
2026-06-23
LOW
NEUTRAL
CORR0.15
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
$LEGN
◈ ESEN AI
Calidi Biotherapeutics announced the appointment of Corsee Sanders, a veteran biotech executive with 30+ years at major pharmaceutical firms including Genentech, Roche, and Celgene, to its board of directors. This move …
MANILATIMES.NET
·
2026-06-17
NEUTRAL
NEUTRAL
CORR0.15
Legend Biotech Corporation Announces Proposed Public Offering
$LEGN
◈ ESEN AI
LEGN announced a $225 million underwritten public offering of American Depositary Shares, with underwriters granted a 30-day option to purchase an additional 15% at the offering price. This capital raise is subject to m…
MANILATIMES.NET
·
2026-06-14
HIGH
BULLISH
CORR0.72
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
$LEGN
$JNJ
◈ ESEN AI
Legend Biotech announced Phase 1 clinical proof-of-concept for LB2501, an in vivo dual-targeting CAR-T therapy designed to treat relapsed/refractory B-cell non-Hodgkin lymphoma. The milestone represents a significant va…
EXPLORE OTHER FILTERS